Ubs Group Ag Immunome Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Immunome Inc. stock. As of the latest transaction made, Ubs Group Ag holds 79,240 shares of IMNM stock, worth $788,438. This represents 0.0% of its overall portfolio holdings.

Number of Shares

79,240

Previous 77,683 2.0%

Holding current value

$788,438

Previous $939,000 23.32%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$11.7 - $16.51 $18,216 - $25,706	1,557 Added 2.0%	79,240 $1.16 Million
Q2 2024 Aug 13, 2024	BUY	$11.54 - $22.11 $611,989 - $1.17 Million	53,032 Added 215.13%	77,683 $939,000
Q1 2024 May 13, 2024	BUY	$11.01 - $27.34 $271,407 - $673,958	24,651 New	24,651 $608,000
Q3 2023 Nov 09, 2023	SELL	$6.17 - $9.16 $6,441 - $9,563	-1,044 Reduced 98.68%	14 $0
Q2 2023 Aug 11, 2023	BUY	$4.7 - $7.91 $4,906 - $8,258	1,044 Added 7457.14%	1,058 $8,000
Q1 2023 May 12, 2023	SELL	$3.26 - $5.69 $1,499 - $2,617	-460 Reduced 97.05%	14 $0
Q4 2022 Feb 08, 2023	SELL	$2.21 - $5.0 $32,701 - $73,985	-14,797 Reduced 96.9%	474 $1,000
Q3 2022 Nov 10, 2022	BUY	$3.39 - $6.14 $47,266 - $85,610	13,943 Added 1049.92%	15,271 $68,000
Q2 2022 Aug 10, 2022	BUY	$2.24 - $5.79 $2,705 - $6,994	1,208 Added 1006.67%	1,328 $4,000
Q1 2022 May 16, 2022	SELL	$3.88 - $13.99 $9,199 - $33,170	-2,371 Reduced 95.18%	120 $1,000
Q4 2021 Feb 14, 2022	BUY	$12.96 - $23.44 $32,101 - $58,060	2,477 Added 17692.86%	2,491 $32,000
Q3 2021 Nov 15, 2021	SELL	$12.5 - $27.76 $16,950 - $37,642	-1,356 Reduced 98.98%	14 $0
Q2 2021 Aug 13, 2021	BUY	$16.33 - $32.33 $15,056 - $29,808	922 Added 205.8%	1,370 $24,000
Q1 2021 May 12, 2021	SELL	$9.56 - $43.24 $5,602 - $25,338	-586 Reduced 56.67%	448 $15,000
Q4 2020 Feb 11, 2021	BUY	$9.46 - $14.16 $9,781 - $14,641	1,034 New	1,034 $10,000

Others Institutions Holding IMNM

# of Institutions

121

Shares Held

47.1M

Call Options Held

322K

Put Options Held

1.91M

View Full List

About Immunome Inc.

Ticker IMNM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,127,400
Market Cap $121M
Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product ca...

More about IMNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account